Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Feb 2022
Understanding innovation of health technology assessment methods: the IHTAM framework
31 January 2022 - Adequate methods are urgently needed to guarantee the good practice of health technology assessment for technologies with ...
Posted by Michael Wonder on 02 Feb 2022
Biden promised 500 million free Covid tests. Then he had to find them.
2 February 2022 - Millions of Americans are now receiving tests through the new mail program, which health experts said came ...
Posted by Michael Wonder on 02 Feb 2022
FDA approves first generic of Restasis
2 February 2022 - The U.S. FDA has approved the first generic of Restasis (cyclosporin ophthalmic emulsion) 0.05% single use vials ...
Posted by Michael Wonder on 02 Feb 2022
Olaparib a 'no go' for patients with breast cancer in England
2 February 2022 - Olaparib has been approved to treat patients with BRCA mutation positive HER2 negative metastatic breast cancer after ...
Posted by Michael Wonder on 02 Feb 2022
QSAM Biosciences receives rare paediatric disease designation from FDA for CycloSam in the treatment of osteosarcoma
2 February 2022 - QSAM Biosciences today announces that the United States FDA has granted rare paediatric disease designation to ...
Posted by Michael Wonder on 02 Feb 2022
Jazz Pharmaceuticals completes U.S. FDA supplemental biologics license application for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday dosing schedule
2 February 2022 - Phase 2/3 trial data, the basis for submission, demonstrates Rylaze maintains a clinically meaningful level of nadir ...
Posted by Michael Wonder on 02 Feb 2022
New order: European cancer coalition calls for cancer treatment overhaul
2 February 2022 - Coalition urges reformation of EU wide drug research and development to drive treatment optimisation ...
Posted by Michael Wonder on 02 Feb 2022
UK’s Early Access to Medicines Scheme now to be put on a legal footing
2 February 2022 - Significant clarification of the life-changing Early Access to Medicines Scheme to be introduced into law. ...
Posted by Michael Wonder on 02 Feb 2022
Register study on gene therapy with Zolgensma starts
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...
Posted by Michael Wonder on 02 Feb 2022
ABPI analysis on NICE’s changes for evaluating new medicines: next steps
31 January 2022 - NICE has published a new Manual, which sets out how the latest medicines and health technologies ...
Posted by Michael Wonder on 02 Feb 2022
New EU regulation on health technology assessment of cancer medicines
1 February 2022 - On Dec 15, 2021, the EU adopted a new regulation to harmonise health technology assessment of new ...
Posted by Michael Wonder on 02 Feb 2022
Global consequences of the US FDA's accelerated approval of cancer drugs
1 February 2022 - The accelerated approval system is a fast track drug approval pathway created by the US FDA in ...
Posted by Michael Wonder on 02 Feb 2022
Review of the National Medicines Policy – consultation on the draft closes 16 February 2022
2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...
Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use ...
Posted by Michael Wonder on 02 Feb 2022
Universal health care bill fails to pass in California
1 February 2022 - A bill that would have created the nation's only universal health care system has failed to pass ...